

April 19<sup>th</sup>, 2021

## Study shows Sinovac vaccine is 67% effective against symptomatic infection

**Santiago, April 19<sup>th</sup>, 2021.** The Ministry of Health recently published preliminary results on the effectiveness of the CoronaVac vaccine (Sinovac) to the SARS-CoV-2 in Chile. The study considered 10.5 million people, of which 4 million were inoculated with the Sinovac vaccine between February 2nd and April 1st 2021. Different outcomes were compared between vaccinated and not-vaccinated groups, taking into account several characteristics including age, sex, region of residence, income level, comorbidities, and nationality. Results will be updated on a monthly basis.

In summary, the effectiveness of the Sinovac vaccine at the 14th day after the second dose is as follows:

- 67% in preventing symptomatic infection of COVID-19;
- 85% in preventing hospitalization;
- 89% in preventing ICU hospitalization;
- 80% in preventing death due to COVID-19.

These estimates are consistent with those from preliminary Phase 3 clinical trials in Brazil and Turkey, as well as those published recently by the University of Chile.

The presentation with the results is public and available in Spanish at: [https://www.minsal.cl/wp-content/uploads/2021/04/20210416\\_ESTUDIO-EFECTIVIDAD-CORONAVAC.pdf](https://www.minsal.cl/wp-content/uploads/2021/04/20210416_ESTUDIO-EFECTIVIDAD-CORONAVAC.pdf)